AZD9291 40 mg + AZD9291 80 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Conditions
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Trial Timeline
Aug 24, 2015 → Sep 27, 2019
NCT ID
NCT02529995About AZD9291 40 mg + AZD9291 80 mg
AZD9291 40 mg + AZD9291 80 mg is a phase 1 stage product being developed by AstraZeneca for Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive. The current trial status is completed. This product is registered under clinical trial identifier NCT02529995. Target conditions include Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02529995 | Phase 1 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive